Fluciclovine F18 vs Ipilimumab
Fluciclovine F18 vs Ipilimumab: Overview
This comparison examines the pharmacological differences between Fluciclovine F18 and Ipilimumab.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days.
Chemical Properties
Type: Fluciclovine F18 β Small molecule; Ipilimumab β Antibody.